These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 24290875)

  • 21. Analysis of Prescribers' Notes in Electronic Prescriptions in Ambulatory Practice.
    Dhavle AA; Yang Y; Rupp MT; Singh H; Ward-Charlerie S; Ruiz J
    JAMA Intern Med; 2016 Apr; 176(4):463-70. PubMed ID: 26954486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Encouraging the use of generic medicines: implications for transition economies.
    King DR; Kanavos P
    Croat Med J; 2002 Aug; 43(4):462-9. PubMed ID: 12187525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estimating efficiency of Directive 2011/24/EU cross-border healthcare in member states.
    Ibrahim MD; Hocaoglu MB; Numan B; Daneshvar S
    J Comp Eff Res; 2018 Aug; 7(8):827-834. PubMed ID: 29770704
    [No Abstract]   [Full Text] [Related]  

  • 24. Regulatory Capture in Pharmaceutical Policy Making: The Case of National Medicine Agencies Related to the EU Falsified Medicines Directive.
    Borup R; Traulsen JM; Kaae S
    Pharmaceut Med; 2019 Jun; 33(3):199-207. PubMed ID: 31933284
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of the EU Directive on patients' rights and cross border health care in Malta.
    Azzopardi-Muscat N; Aluttis C; Sorensen K; Pace R; Brand H
    Health Policy; 2015 Oct; 119(10):1285-92. PubMed ID: 26365283
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between EU guidelines and vaccination in Germany between 2011 and 2017 : How healthcare legislation of the EU has influenced access to vaccination for senior citizens in Germany since 2011.
    Azadi B
    Z Gerontol Geriatr; 2019 Dec; 52(8):782-788. PubMed ID: 31650228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Review of the development in European Legislation on the harmonisation of the laws for medicinal products].
    Lehmann B
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 Jul; 51(7):713-21. PubMed ID: 18584107
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ethical assessment of the EU health policy under the Directive 2011∕24∕EU: approaching patients' rights and cross-border healthcare.
    Olimid AP; Olimid DA
    Rom J Morphol Embryol; 2019; 60(2):729-735. PubMed ID: 31658352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Attitudes of physicians and pharmacists towards International Non-proprietary Name prescribing in Belgium.
    Van Bever E; Elseviers M; Plovie M; Vandeputte L; Van Bortel L; Vander Stichele R
    Basic Clin Pharmacol Toxicol; 2015 Mar; 116(3):264-72. PubMed ID: 25155133
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of legislation, regulations and national health strategies for palliative care in seven European countries (Results from the Europall Research Group): a descriptive study.
    Van Beek K; Woitha K; Ahmed N; Menten J; Jaspers B; Engels Y; Ahmedzai SH; Vissers K; Hasselaar J
    BMC Health Serv Res; 2013 Jul; 13():275. PubMed ID: 23866928
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients' Rights in Cross-border Healthcare (Directive 2011/24/EU) and How It Applies to Turkey as a Negotiating Candidate Country.
    Ekmekci PE
    Eur J Health Law; 2017; 24(4):432-444. PubMed ID: 29203967
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Right of access to health care for undocumented migrants in EU: a comparative study of national policies.
    Cuadra CB
    Eur J Public Health; 2012 Apr; 22(2):267-71. PubMed ID: 21659389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Evaluation of prescription practices and of the rational use of medicines in Niger].
    Mallet HP; Njikam A; Scouflaire SM
    Sante; 2001; 11(3):185-93. PubMed ID: 11641083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmaceutical Manufacturing in the EU and the EU-US Mutual Recognition Agreement.
    Gaspar Ernesto LM; Dias Loureiro RM
    PDA J Pharm Sci Technol; 2020; 74(6):617-626. PubMed ID: 32540862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European activities in radiation protection in medicine.
    Simeonov G
    Radiat Prot Dosimetry; 2015 Jul; 165(1-4):34-8. PubMed ID: 25870434
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Think INN, prescribe INN, dispense INN: good professional practice.
    Prescrire Int; 2000 Dec; 9(50):184-90. PubMed ID: 11475502
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-border healthcare directive: Assessing stakeholders' perspectives in Poland and Portugal.
    Helena R
    Health Policy; 2016 Apr; 120(4):369-76. PubMed ID: 26948704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Paying for formerly free medicines in Spain after 1 year of co-payment: changes in the number of dispensed prescriptions.
    Puig-Junoy J; Rodríguez-Feijoó S; Lopez-Valcarcel BG
    Appl Health Econ Health Policy; 2014 Jun; 12(3):279-87. PubMed ID: 24696429
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.